Articles On Amplia Therapeutics (ASX:ATX)

Drug developer Amplia Therapeutics Ltd (ASX:ATX) has announced the enrolment of 26 patients as part of its clinical trial – dubbed ‘ACCENT’ – to test the use of its drug narmafotinib in the treatment of advanced pancreatic cancer. The pa...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

By Tim Boreham, Editor, The New Criterion ASX code: ((ATX)) Market cap: $17.93m Shares on issue: 271,609,233 Chief executive officer: Dr Chris Burns (co-founder) Board: Dr Warwick Tong (chair), Dr Burns, Dr Robert Peach, Jane Bell Financial...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involving its FAK-inhibitor narmafotinib in combination with gemcitabine and abraxane.

Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that treats solid tumours in advanced pancreatic cancer patients. The ACCENT trial, conducted in two stages, assesses the safety and efficacy...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc   Amplia reports promising data from pancreatic cancer trial Amplia The...

Amplia Therapeutics (ASX:ATX) receives $2.4 million from the government The money comes as part of a national research and development tax incentive The R&D work done relates to the company’s ongoing pancreatic cancer trial...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA.  Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports. By Tim Boreham ASX Code: ((TLX)) Share price: $11.26 Shares on issue: 318,808,268 Market cap: $3.58 billion Chief executive officer: Dr Christian Behr...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

HIGHLIGHTS Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer FOLFIRINOX is the most widely used treatment for pancreatic cancer patients...

Tissue Repairs and Radiopharm surge after US FDA meetings Avecho granted application approval by US Patent Office Amplia demonstrated efficacy of its pancreatic drug   Tissue Repair to progress to Phase 3 Wound healing specialist Tissue R...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Amplia Therapeutics (ASX:ATX) has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the company’s FAK inhibitors.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX opened lower this morning, while majority of the sectors dragged. Finance and communications fell 0.5 per cent, while healthcare also took a hit – down 0.13 per cent. However, Amplia Therapeutics (ATX) appeared immune to the...

Amplia Therapeutics (ATX) receives grant funding to support research collaboration with Australia’s national science agency, CSIRO The company will work with CSIRO to develop formulations of its small molecule FAK inhibitors that can be...

The ASX is set to fall modestly lower on Monday on debt ceiling uncertainties Foot Locker plunged 27% after slow sales in Q1 Climate and energy set to be established as the third pillar of the Australia-US alliance   Aussie shares are se...

Amplia Therapeutics (ASX:ATX) has announced the completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Amplia Therapeutics (ATX) recruits and doses the first patient in cohort three of its ongoing ACCENT trial for pancreatic cancer Under the third cohort, patients will receive an increased dosage of ATX’s AMP945 product, following the sa...

The ASX is expected to open flat on Wednesday following a muted session on Wall Street. Yesterday, the RBA released its April minutes for when it decided to pause further rates hikes, detailing that it was a close but necessary decision...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Amplia Therapeutics (ATX) appoints Christopher Burns as CEO and Managing Director, effective from December 5Dr Burns has more than 30 years of experience in drug discovery and development and has served in multiple executive positions for p...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

27 new biotech companies listed on the ASX the last two years Australian companies need access to US capital to grow The AusBiotech investment conference kicks off next week in WA   The Covid-19 pandemic put Australia’s biotechnology sect...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Amplia Therapeutics (ATX) releases data from two mice studies, showing potential for its AMP886 drug to reduce cancer in patients with acute myeloid leukaemia (AML)One study showed mice inoculated with MV4-11 cells who were then treated wit...

ASX 200 gains 1%  Small Caps index does the same, but then gives it all back ODE wins and NIC MD Justin Werner: Hengjaya joins world’s best nickel resources   The ASX Emerging Companies index (XEC) has given all away its early gains on Mo...

Dr John Lambert (ATX) resigns as CEO and Managing Director from Amplia Therapeutics, effective NovemberThe company says he will be available to assist with an orderly transition of the role and has commenced the search for a new CEOCommenti...